Back to Search
Start Over
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
- Source :
- Lancet respiratory medicine, 2(5), 395-404. Elsevier Limited, Muthuri, S G, Venkatesan, S, Myles, P R, Leonardi-Bee, J, Al Khuwaitir, T S A, Al Mamun, A, Anovadiya, A P, Azziz-Baumgartner, E, Baez, C, Bassetti, M, Beovic, B, Bertisch, B, Bonmarin, I, Booy, R, Borja-Aburto, V H, Burgmann, H, Cao, B, Carratala, J, Denholm, J T, Dominguez, S R, Duarte, P A D, Dubnov-Raz, G, Echavarria, M, Fanella, S, Gao, Z C, Gerardin, P, Giannella, M, Gubbels, S, Herberg, J, Iglesias, A L H, Hoger, P H, Hu, X Y, Islam, Q T, Jimenez, M F, Kandeel, A, Keijzers, G, Khalili, H, Knight, M, Kudo, K, Kusznierz, G, Kuzman, I, Kwan, A M C, Amine, I L, Langenegger, E, Lankarani, K B, Leo, Y S, Linko, R, Liu, P, Madanat, F, Mayo-Montero, E, McGeer, A, Memish, Z, Metan, G, Mickiene, A, Mikic, D, Mohn, K G I, Moradi, A, Nymadawa, P, Oliva, M E, Ozkan, M, Parekh, D, Paul, M, Polack, F P, Rath, B A, Rodriguez, A H, Sarrouf, E B, Seale, A C, Sertogullarindan, B, Siqueira, M M, Skret-Magierlo, J, Stephan, F, Talarek, E, Tang, J W, To, K K W, Torres, A, Torun, S H, Tran, D, Uyeki, T M, van Zwol, A, Vaudry, W, Vidmar, T, Yokota, R T C, Zarogoulidis, P & Nguyen-Van-Tam, J S 2014, ' Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data ', Lancet respiratory medicine, vol. 2, no. 5, pp. 395-404 . https://doi.org/10.1016/S2213-2600(14)70041-4
- Publication Year :
- 2014
-
Abstract
- Background: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, but evidence for their effectiveness in reducing mortality is uncertain. We did a meta-analysis of individual participant data to investigate the association between use of neuraminidase inhibitors and mortality in patients admitted to hospital with pandemic influenza A H1N1pdm09 virus infection. Methods: We assembled data for patients (all ages) admitted to hospital worldwide with laboratory confirmed or clinically diagnosed pandemic influenza A H1N1pdm09 virus infection. We identified potential data contributors from an earlier systematic review of reported studies addressing the same research question. In our systematic review, eligible studies were done between March 1, 2009 (Mexico), or April 1, 2009 (rest of the world), until the WHO declaration of the end of the pandemic (Aug 10, 2010); however, we continued to receive data up to March 14, 2011, from ongoing studies. We did a meta-analysis of individual participant data to assess the association between neuraminidase inhibitor treatment and mortality (primary outcome), adjusting for both treatment propensity and potential confounders, using generalised linear mixed modelling. We assessed the association with time to treatment using time-dependent Cox regression shared frailty modelling. Findings: We included data for 29234 patients from 78 studies of patients admitted to hospital between Jan 2, 2009, and March 14, 2011. Compared with no treatment, neuraminidase inhibitor treatment (irrespective of timing) was associated with a reduction in mortality risk (adjusted odds ratio [OR] 0·81; 95% CI 0·70-0·93; p=0·0024). Compared with later treatment, early treatment (within 2 days of symptom onset) was associated with a reduction in mortality risk (adjusted OR 0·48; 95% CI 0·41-0·56; p
- Subjects :
- Male
ANTIVIRAL TREATMENT
IMPACT
Respiratory System
CHILDREN
Neuraminidase inhibitors
Pandemic influenza
Mortality
Meta-analysis
medicine.disease_cause
THERAPY
chemistry.chemical_compound
Influenza A Virus, H1N1 Subtype
0302 clinical medicine
Pandemic
Influenza A Virus
Influenza A virus
Zanamivir
030212 general & internal medicine
Enzyme Inhibitors
Child
OUTCOMES
0303 health sciences
biology
Neuraminidase inhibitor
Medicine (all)
virus diseases
Middle Aged
3. Good health
Hospitalization
Treatment Outcome
Female
Life Sciences & Biomedicine
Adolescent
Adult
Antiviral Agents
Humans
Influenza, Human
Neuraminidase
Oseltamivir
Proportional Hazards Models
Young Adult
Pandemics
Pulmonary and Respiratory Medicine
Human
medicine.drug
medicine.medical_specialty
medicine.drug_class
PANDEMIC INFLUENZA
Article
PRIDE Consortium Investigators
03 medical and health sciences
Critical Care Medicine
General & Internal Medicine
Internal medicine
medicine
H1N1 Subtype
Intensive care medicine
Science & Technology
030306 microbiology
business.industry
STEM-CELL TRANSPLANTATION
ADULTS
Odds ratio
Influenza
chemistry
RISK-FACTORS
biology.protein
business
Subjects
Details
- ISSN :
- 22132600
- Database :
- OpenAIRE
- Journal :
- Lancet respiratory medicine, 2(5), 395-404. Elsevier Limited, Muthuri, S G, Venkatesan, S, Myles, P R, Leonardi-Bee, J, Al Khuwaitir, T S A, Al Mamun, A, Anovadiya, A P, Azziz-Baumgartner, E, Baez, C, Bassetti, M, Beovic, B, Bertisch, B, Bonmarin, I, Booy, R, Borja-Aburto, V H, Burgmann, H, Cao, B, Carratala, J, Denholm, J T, Dominguez, S R, Duarte, P A D, Dubnov-Raz, G, Echavarria, M, Fanella, S, Gao, Z C, Gerardin, P, Giannella, M, Gubbels, S, Herberg, J, Iglesias, A L H, Hoger, P H, Hu, X Y, Islam, Q T, Jimenez, M F, Kandeel, A, Keijzers, G, Khalili, H, Knight, M, Kudo, K, Kusznierz, G, Kuzman, I, Kwan, A M C, Amine, I L, Langenegger, E, Lankarani, K B, Leo, Y S, Linko, R, Liu, P, Madanat, F, Mayo-Montero, E, McGeer, A, Memish, Z, Metan, G, Mickiene, A, Mikic, D, Mohn, K G I, Moradi, A, Nymadawa, P, Oliva, M E, Ozkan, M, Parekh, D, Paul, M, Polack, F P, Rath, B A, Rodriguez, A H, Sarrouf, E B, Seale, A C, Sertogullarindan, B, Siqueira, M M, Skret-Magierlo, J, Stephan, F, Talarek, E, Tang, J W, To, K K W, Torres, A, Torun, S H, Tran, D, Uyeki, T M, van Zwol, A, Vaudry, W, Vidmar, T, Yokota, R T C, Zarogoulidis, P & Nguyen-Van-Tam, J S 2014, ' Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data ', Lancet respiratory medicine, vol. 2, no. 5, pp. 395-404 . https://doi.org/10.1016/S2213-2600(14)70041-4
- Accession number :
- edsair.doi.dedup.....7318e100d7587a05555cf5dd3661812f